Shattuck Labs (STTK)

• Market cap: $455M
• 1 day: -0.67%
• 5 days: -3.1%
• 1 month: -16.36%
• 3 months: 48.25%
• 6 months: 146.06%
• Year to date: 59.84%
• 1 year: 449.07%
• 5 years: -78.49%
• 10 years: -69.35%
• Sector: Healthcare
• Industry: Biotechnology

About: Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Employees: 40